| DCC3846 |
Nvp-saa164 |
Novel nonpeptide bradykinin B1 receptor antagonist |
|
| DCC3847 |
Nvp-sra880 |
The first non-peptide somatostatin sst(1) receptor antagonist |
|
| DCC3848 |
Nvp-tac544 |
Novel focal adhesion kinase (FAK) inhibitor, potently blocking kinase activity of FAK along with Aurora A, activated Cdc42-associated kinase 1 (ACK1), Met, insulin receptor (IR), TrkA, and IGF-1R |
|
| DCC3849 |
Nvp-vid400 |
Specific inhibitor of the 25-hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase) |
|
| DCC3850 |
Nvp-xaa228 |
Novel potent PKCθ inhibitor |
|
| DCC3851 |
Nvs-bet-2 |
Novel selective bromodomain and extra-terminal domain (BET) protein family inhibitor (BETi ), inducing an ‘activated’ keratinocyte transcriptional profile with reversal of chronic wound biomarkers in human skin ex vivo |
|
| DCC3852 |
Nvs-mllt-1 |
Novel Potent and Selective inhibitor of YEATS proteins |
|
| DCC3853 |
Nvs-pak1-c |
Negative control for NVS-PAK1-1 (8778) |
|
| DCC3854 |
Nvs-sm2 |
Potent, orally active, small-molecule enhancer of SMN2 splicing, binding to and stabilizing the U1 snRNP:5′ss RNA complex |
|
| DCC3855 |
Nvx-108 |
Exceptional oxygen transporter, increasing brain tissue oxygen tension (PbtO2) when administered soon after traumatic brain injury (TBI) |
|
| DCC3856 |
Nw-1772 |
Highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor |
|
| DCC3857 |
Nxd30001 |
Novel potent Hsp90 inhibitor, inducing tumor regression in a genetically engineered mouse model of glioblastoma multiforme |
|
| DCC3858 |
nxn-188 |
Selective nNOS inhibitor and a5-HT1B/1D receptor agonist |
|
| DCC3859 |
Nybomycin |
Anti-microbial agent against Mycobacterium smegmatis and Mycobacterium bovis BCG, binding to DNA and inducing a unique morphological change to mycobacterial bacilli leading the bacterial cell death |
|
| DCC3860 |
Ny-eso-1 |
Cancer-testis antigen (CTA) with re-expression in numerous cancer types, eliciting spontaneous humoral and cellular immune responses, restricting expression pattern, being a good candidate target for cancer immunotherapy |
|
| DCC3861 |
Nystatin-3 |
Novel water-soluble nystatin derivative, being fully water-soluble (up to 1 g/mL) with the same potency of Nystatin but with 13.5 times lower toxicity |
|
| DCC3862 |
O-1302 |
Potent CB1 receptor antagonist |
|
| DCC3863 |
O-1663 |
Novel inhibitor of advanced stages of breast cancer, targeting multiple cannabinoid anti-tumour pathways |
|
| DCC3864 |
o-1918 |
Novel GPR18 antagonist, blocking the effects of Abn-CBD and NAGly. |
|
| DCC3865 |
Oa-adp-hpd |
Poly(ADP-Ribose) Glycohydrolase (PARG) inhibitor |
|
| DCC3866 |
Oat-1441 |
Novel Selective and Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase (hAMCase) |
|
| DCC3867 |
O-bn-thaz Fumarate |
Potent agonist of the human 5-HT2A and 5-HT2C receptors |
|
| DCC3868 |
Obtusaquinone
Featured
|
Obtusaquinone (OBT) is a potent antineoplastic agent with significant therapeutic potential, particularly in aggressive cancers such as glioblastoma and breast cancer. Its mechanism of action involves the induction of oxidative stress and endoplasmic reticulum (ER) stress, leading to cancer cell death. OBT has demonstrated promising in vivo activity, including the ability to penetrate the blood-brain barrier (BBB) and target brain tumors, making it a particularly valuable candidate for treating central nervous system (CNS) malignancies. |
|
| DCC3869 |
Obtusilactone A |
Inhibitor of mitochondrial Lon protease and activator of DNA damage checkpoints |
|
| DCC3870 |
Obtusilactone B
Featured
|
Specific inhibitor of vaccinia-related kinase 1 (VRK1)-mediated phosphorylation of barrier-to-autointegration factor (BAF) |
|
| DCC3871 |
O-carbamate 66 |
Novel potent antileishmanial and antitrypanosomal agent, offering a more optimal balance of increased solubility, suitable metabolic stability, excellent oral bioavailability (100%), and strong in vivo efficacy in a visceral leishmaniasis mouse model (97% |
|
| DCC3872 |
Ocean Blue Se |
Blue fluorescent labeling reagent |
|
| DCC3873 |
Octamoxin |
Irreversible and nonselective Monoamine_oxidase_inhibitor>monoamine oxidase inhibitor (MAOI) |
|
| DCC3874 |
Octimibate |
Potent non-prostanoid inhibitor of platelet aggregation, acting via the prostacyclin receptor |
|
| DCC3875 |
Octreotideacetate
Featured
|
Agonist of sst2, sst3 and sst5 somatostatin receptors |
|
